Therefore, this study aimed to explore the relationship between creatinine/cystatin C ratio and progression-free survival (PFS) and overall survival (OS) in CRC patients undergoing surgical treatment, and develop a novel prognostic model based on creatinine/cystatin C ratio to accurately predict clinical outcomes. The gene discussed is CST3; the disease is colorectal carcinoma.